{"name":"Sermonix Pharmaceuticals Inc.","slug":"sermonix-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Fulvestrant in combination with abemaciclib","genericName":"Fulvestrant in combination with abemaciclib","slug":"fulvestrant-in-combination-with-abemaciclib","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"Lasofoxifene in combination with abemaciclib","genericName":"Lasofoxifene in combination with abemaciclib","slug":"lasofoxifene-in-combination-with-abemaciclib","indication":"Hormone receptor-positive, HER2-negative breast cancer (postmenopausal women)","status":"phase_3"}]}],"pipeline":[{"name":"Fulvestrant in combination with abemaciclib","genericName":"Fulvestrant in combination with abemaciclib","slug":"fulvestrant-in-combination-with-abemaciclib","phase":"phase_3","mechanism":"Fulvestrant blocks estrogen receptors while abemaciclib inhibits CDK4/6, together suppressing hormone-driven breast cancer cell growth through dual pathway inhibition.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"],"catalyst":""},{"name":"Lasofoxifene in combination with abemaciclib","genericName":"Lasofoxifene in combination with abemaciclib","slug":"lasofoxifene-in-combination-with-abemaciclib","phase":"phase_3","mechanism":"Lasofoxifene is a selective estrogen receptor modulator (SERM) that blocks estrogen signaling, combined with abemaciclib, a CDK4/6 inhibitor that prevents cell cycle progression in hormone receptor-positive breast cancer cells.","indications":["Hormone receptor-positive, HER2-negative breast cancer (postmenopausal women)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOa0lLV3hPaklOWjNJNFp2N1QtdklBR2JZR0cwMXE2d2dSRVVpaFp6Z1daajhsRzlPR2VNOFBaQXlVejBpSWRrVEpoNzdhVHFWMVZaMzhSTXk3blZyRmY3aDRud2hjNmdoTkUxY2oxaFVZeDNRTnFpc3V2eDJLYzMwWFo2Qm5zTElITXlOcWRxVkFfZXg2RXN5bHJ3ZDdZLWlFNjUwelJZNkYxVFR1WVJR?oc=5","date":"2026-03-31","type":"trial","source":"Stock Titan","summary":"LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend - Stock Titan","headline":"LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNQjNRdGU1UFVxLU5OMTRCekVtclNNU094eFFuN3pXNnd6RlJGbWVJOHFyREpYcFUyeTVuWFBGWFJ5LXlCSXpGN0NBUEtRaEtxMVdfQU43V2dkWHc4WHJMSjZ5OS1vS0dPY09uYnE0YnR3SmZkMGtkZkpJNzYyRThpM0tGR3lqN3ZmNUtHbg?oc=5","date":"2026-01-09","type":"pipeline","source":"Fierce Pharma","summary":"Athira Pharma roars into the new year with rebrand to LeonaBio - Fierce Pharma","headline":"Athira Pharma roars into the new year with rebrand to LeonaBio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOTHFsdWRxbWd1NVJyWEIwR3U5WjBUZkhWZW1jeVZmLTBIMHEweUx5VWQ1dnlSWVE3OTgtRTNPWks4ZmVUdS1XSy1UVWR3c0Y4ekx0MDZMcmlpVERDT0VGTXFGZF93WW9FVEpPbVFzcW1Ib1V1RHMwUUNEbDlnWTZzSms0UFpIcDlpSVBPRHN0TE95Q0REdjNHUDRmZnhQMk1pM2RscTZKREstUkdFMzRjWEtydmp6a3dJTGhQNUlB?oc=5","date":"2025-12-18","type":"pipeline","source":"GeekWire","summary":"Athira Pharma recovers from Alzheimer’s failure with breast cancer pivot and $90M investment - GeekWire","headline":"Athira Pharma recovers from Alzheimer’s failure with breast cancer pivot and $90M investment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPWUN4T0J1UFpsVVp6OG96ZlJsdzBFaG9mSWQ0ZWhxUGRXYWRHalVhY3VYekN0TUpRZmE3ek85cWg3R2xJRFJTTDhNaUwwcEI3QjZIRVhFdm5aTWtzMGY2TXZNcTJrODVwM3lmLWdvbUtOajlKMjFGXzNBOWZKRmhheElHYjRDc3ZvS0FXNkVTdEJiaGwybmJQR1FnOEEwcGFzV2lReldZQ2tkX3pQc0tHd1dGSzBnVWh1ckVF?oc=5","date":"2025-12-18","type":"trial","source":"Fierce Biotech","summary":"Athira inks Sermonix deal to power ex-Pfizer asset toward phase 3 breast cancer data - Fierce Biotech","headline":"Athira inks Sermonix deal to power ex-Pfizer asset toward phase 3 breast cancer data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxNMTVfVU9jQUFLNS1DRlRoQkZNdEl1S05zZUU3Uzk5RjlESy1WVDVRaEVMWmZENnNSMzhZM19ZaU1oOElOMFlBc0loSVRWWVMwN3NrU045d2hqUTdvdU5MXzZfZ0czMTA0YjBxNVdUNzVYVENPNTVFTF8xN2poNTUzYkxrMXRPeDJrWDhMRVFCa3BKRWd2ZlVVRjhEVXh6TjN0YTkySV9iMkZLMEk3dUpKZDNDY2ZUeUtTQkxYdzNWU1hHQndDU2VFbjVsWVNOUFE4VDl5T19XLXVfVnJQSzY1Y2w2RUdHaVRYQXBZYW9zczRfWXQxSmVxNGVYRWFwTG1URUZLbm9FNHRJN0doQ18xUnEtQXlMcEVYRFJxbEVHZWVNTWJPYldnVGgyTzBmMHJFeW9HMlBwTVZobmVKOXFpbGRLRThiajR4bFlJNnNyN1BfWUF2?oc=5","date":"2025-12-18","type":"trial","source":"GlobeNewswire","summary":"Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million - GlobeNewswire","headline":"Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candi","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQcnlROXpyR3k3cV95UEE4RnVvTFNXdVVzV0FvaWlsLXhUYm5yVk4zWkI1TGZObVlnYzh6cGRZaXNBYVluTDZQZC1BRFRKajJhc2tEOUhUOFBOb0NHdVlGOE5tLTl0VUJ2MVlfMVZWYlNEX2U1QXdGMG0tRWI2Z3JiM0NlaWc3a2Q2MG8tR2NwQUZKaXB5c2o4MTJsU0hJdmJtb0kwbnhJekJvTlNiLUd3dngteFludE0?oc=5","date":"2025-12-18","type":"trial","source":"Investing.com","summary":"Athira Pharma acquires rights to phase 3 breast cancer drug - Investing.com","headline":"Athira Pharma acquires rights to phase 3 breast cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNWkZlNU9vS0Y4aklkaU5XVHk4dm5BZF9GZjZ5V3hrN19VZDJoUUQyWXBReEdnV1ZLMElUS2VXS09XSTcyaXlKX3lfcTJnNV9kRmU4eVlIM1pEZ0c4SldLXzJkczlBa1Y1akdBYzU0NDU2eVFTUTc1WEd6Q3RYOThsS1YzNjRSZlE3OUdWcWdLaUd1ZkpkV1lEVkRhTnI?oc=5","date":"2025-12-18","type":"pipeline","source":"The Business Journals","summary":"Athira Pharma raises $90 million as Bothell firm shifts focus - The Business Journals","headline":"Athira Pharma raises $90 million as Bothell firm shifts focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNUHVzTE1lbmNEY1F3Z2F5cHkya1RpZ25oNVhlbEJGZ256WEc1ejdZUDdCXzNjV29GSjFEeDgwMmxZb0g4Y1Q3dV96eE1aNXpTSFNLWTZhM3cwdHZTcDFOUXk2UXBpQnFQYmpzSjEyNlhIOVBhTXpMa3NuQjB5Mm1vY2N1ay1hUElZOEVucEtYazNxdkloRTJnRkZNamYzVTd4TGc?oc=5","date":"2025-12-18","type":"deal","source":"Blockonomi","summary":"Athira Pharma (ATHA) Stock Explodes 73% Higher on Breakthrough Cancer Drug Deal - Blockonomi","headline":"Athira Pharma (ATHA) Stock Explodes 73% Higher on Breakthrough Cancer Drug Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBmdE5za1VGbWxVdjFMREVPVWlTc1Jtb3drSERXMEloZ2VlcTZnamttOWVLSXZ3RTNZMV81ZEp6R0RsSGRHT1RkVGg0QTdlYVVoa183Y2F0QnVLRWQydVpaVmlEZFhGdDBnZkNfZ3NQa1RWN3lmTVRwZkJB?oc=5","date":"2025-12-18","type":"pipeline","source":"TipRanks","summary":"Why Is Athira Pharma Stock (ATHA) Up Today? - TipRanks","headline":"Why Is Athira Pharma Stock (ATHA) Up Today?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQUy1VbU5WOWxrZHlFb0htRWpIR1R6Y21MVFkxUmNNd0dtTFZCZlBCaUVPdXBnQzNHX21GR1ZLbXZkUWdKUE9NYWoyYnlyZWRfUktTOVdqNFVqTFRlMDBUdURwd3pHci1YQlVDREJDWURBNDM1X2toVDdLSjU0UDhiTW42RzRITE5LOGhGZGFuVXZHMnUtajFDV1lrLXlDNVdacmw2LXhDY3VrekNCbC1yVFNCWkxDSGs0ZURIRHRpNDdTSV9yU0pibnlhaTdjSm1GVkc3NGhmQQ?oc=5","date":"2025-12-18","type":"trial","source":"Investing.com","summary":"Athira Pharma stock soars after acquiring rights to Phase 3 breast cancer drug - Investing.com","headline":"Athira Pharma stock soars after acquiring rights to Phase 3 breast cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPVklTY3BmREpOZFdPMjF6LVVWQnZDdklfUHBPZ28zUVBqTlI2WmV4RWdvUTd4VENNQ2JEV2ZFa1l4Qm9pSWN4c3M5cEFITGZrR2E5cmMxZ1lKUWhkazFlWlhDQ2ZyVWhKeFpHc0wtSEtxZzQzUUNyWTAxaVZwZjVMdmRn?oc=5","date":"2025-03-25","type":"pipeline","source":"Pharmaceutical Technology","summary":"Sermonix and Regor to enhance breast cancer treatment options - Pharmaceutical Technology","headline":"Sermonix and Regor to enhance breast cancer treatment options","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFA1Tl9qTkF6LWY2dkJUOGNwUnJkS3dhNHZ4ZWhBaEpNM0xkZUh4T2RKT3BpNEhMYmtaOTgtV0g1eUl3NG8yZS11ekpKNWpIOFRfS2xhYVkzUWZZOHdKWFlwUg?oc=5","date":"2024-01-11","type":"deal","source":"复宏汉霖","summary":"Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene-Media - 复宏汉霖","headline":"Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasof","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}